Sample size determination
There is only one study published in the medical literature regarding the use of IL-3 as a prognostic marker in sepsis. (9) In that study, analysis of IL-3 levels in 97 patients (retrospective data of a previously published prospective cohort with 60 patients and prospective data of a new cohort with 37 patients) revealed that IL-3 was associated with 28-day follow-up mortality in severe sepsis or septic shock patients. Considering a cut-off value of 89.4pg/mL, 38% of deceased patients had IL-3 levels above that value, compared with 11% of the surviving patients, with a 4.9 odds ratio in the Kaplan-Meier survival curve. Global 28-day mortality was 37.1%. In the retrospective phase of the present study, we observed a Figure 1S -Circulating levels of IL-3 on days 1, 3 and 7 according to in-hospital survival. Confidence interval bars with median levels of interleukin-3 (IL-3) and 75 th percentiles on days 1 (D1), 3 (D3), and 7 (D7). * p statistically significant. 27.8% 28-day mortality rate. Considering the prevalence of positive IL-3 (> 89.4pg/mL) in surviving and deceased patients up to the 28th day of the aforementioned study and the allocation ratio of 0.38 in both patient subgroups in our retrospective cohort (i.e., 1 death for every 2.6 survivors), 95 survivors and 36 deaths would be required for a statistical significance to be found between the two groups. Because the primary outcome analyzed in our study was hospital mortality (as opposed to 28-day mortality), the measurement was adjusted considering a 32.9% hospital mortality rate in the first phase of our cohort. Thus, 40 deaths and 81 survivors during hospital stay (yielding a total of 121) would be required for a statistically significant difference to be found between these two subgroups, with a 95% power and 5% α-error.
